We reviewed the records of 33 patients with leukemia who experienced influenza during the period from October 2000 to March 2004. Three (38%) of the 8 patients who did not receive neuraminidase inhibitor therapy and none of the 25 patients who received it died of influenza pneumonia (P p
). The use of neuraminidase inhibitor therapy seems to .001 improve the outcome of influenza in patients with leukemia.
Influenza is associated with significant morbidity and mortality in patients with cancer [1] . Thirty-five percent to 80% of patients with leukemia and influenza develop influenza pneumonia, and up to 43% of patients with leukemia and influenza pneumonia die of infection [2] [3] [4] [5] [6] .
Drugs that specifically target influenza include M2 ion channel-blockers, also known as adamantanes (amantadine and rimantadine), and neuraminidase inhibitors (NAs), which include zanamivir and oseltamivir. Adamantanes are specific inhibitors of influenza A virus replication, but their usefulness is limited by the rapid development of resistant stains of influenza A virus [7] . NAs, in contrast, are active against both the influenza A and influenza B viruses, and to date, NAs have proven far less likely than adamantanes to promote the development of drug-resistant viruses [7] [8] [9] [10] [11] .
To our knowledge, the use of NA therapy among patients with leukemia has not been systematically evaluated. In a pre-vious case report, zanamivir therapy was an effective treatment for influenza in 2 children with acute lymphoblastic leukemia [12] . Herein, we sought to determine the impact of NA therapy on the outcome of patients with leukemia and influenza.
Patients and methods. Patients with leukemia who developed influenza during October 2000-March 2004 were identified using our institution's infection-control database. Patient records were reviewed for demographic characteristics and information on type of leukemia, comorbidities, use of corticosteroid therapy or chemotherapy, neutrophil and lymphocyte counts, concomitant infections, and outcomes.
Respiratory samples were collected from throat swabs, nasopharyngeal wash specimens, and, in some cases, sputum or bronchoalveolar lavage specimens from patients with respiratory symptoms at the primary physicians' discretion. Virological procedures for detecting influenza at our center were reported elsewhere [13] . Chest radiography was commonly performed as part of the initial evaluation of patients with signs and symptoms consistent with upper respiratory infection (URI) or pneumonia. Neutropenia was defined as an absolute neutrophil count of !500 neutrophils/mL. Lymphopenia was defined as an absolute lymphocyte count of !200 lymphocytes/ mL. Antiviral therapy was instituted at the discretion of the treating physician. Oral oseltamivir therapy was administered at a dosage of 75 mg every 12 h. Zanamivir therapy was administered at a dosage of 10 mg every 12 h via oral inhalation. Oral amantadine therapy was administered at a dosage of 100 mg every 12 h. Oral rimantadine therapy was administered at a dosage of 100 mg every 12 h. Aerosolized ribavirin therapy was administered at a daily dosage of 6 g and delivered at a concentration of 20 mg/mL for 18 h/day using a small-particle aerosol generator unit (SPAG-2) via a face mask inside a scavenging tent (to prevent environmental contamination). The use of vaccine or chemoprophylaxis against influenza was not part of the standard practice for these patients. Response to antiviral therapy was defined as complete resolution of clinical and radiologic manifestations of influenza. Response to therapy was assessed if antiviral therapy was administered for у48 h. Patients were observed until resolution of all signs and symptoms of infection or until death. Outcome was assessed at 30 days after diagnosis of influenza. Influenza was considered a contributory cause of death if there was evidence of persistent or progressive influenza at the time of death. Coinfections were considered potential contributory causes of death.
Characteristics of patients with influenza URI or pneumonia were compared. Categorical data were analyzed using the 2-tailed Fisher's exact test (EpiInfo, version 3.2.2; Centers for Disease Control and Prevention). P values р.05 were considered to be statistically significant.
Results. We identified 33 patients with leukemia who developed influenza (table 1). The majority of patients had acute myeloid leukemia, and the majority of patients were in a relapse state of their leukemia. One-third of the patients were receiving induction chemotherapy. Most patients were infected with influenza A virus (67%).
Thirty-two patients (97%) were symptomatic at the time of diagnosis of influenza; the most common symptoms were cough (in 72% of patients), fever (in 61% of patients), and nasal congestion (in 39% of patients). The median duration of symptoms before diagnosis was 3 days (range, 1-7 days). At presentation, 20 patients (61%) had URI, and 13 patients (39%) had developed pneumonia. Compared with patients with pneumonia, patients with URI were less likely to have dyspnea (38% vs. 5% of patients, respectively; ), were more likely to P p .02 have a cough (46% vs. 95% of patients) and runny nose (0% vs. 42% of patients), experienced a shorter duration of symptoms before diagnosis (median, 4 vs. 2 days; ), and P p .02 experienced a shorter length of hospital stay (median days, 8 vs. 3 days;
). However, there was a trend toward patients P p .02 with pneumonia being more likely to have lymphopenia during the onset of influenza (20% of patients with URI vs. 54% of patients with pneumonia;
), and patients with pneu-P p .06 monia were more likely to develop mold infections within 1 month after the onset of influenza (0% of patients with URI vs. 23% of patients with pneumonia;
). P p .05 Fourteen patients (42%) experienced coinfection at the same time or within 1 month either before or after experiencing influenza, which mainly involved the bloodstream (74% of patients) and lungs (63%), with bacteria (64%) being the most common copathogens. Nine patients experienced coinfection within 1 month after the diagnosis of influenza, which mainly involved the bloodstream (67% of patients) and the lungs (33%), with bacteria (44%) and fungi (33%) being the most common copathogens. Hyaline molds, specifically Aspergillus fumigatus (in 2 patients), Aspergillus terreus (in 1 patient), and Fusarium species (in 1 patient), were the pathogenic fungi identified in patients following the onset of influenza.
Twenty-six patients were treated with antiviral therapy; among them, 25 patients (96%) received NA therapy (figure 1), and 1 received amantadine therapy. Fourteen patients (56%) treated with NA therapy had URI, and 11 patients (44%) had pneumonia. Only 1 of 14 patients who were treated with NA therapy during the stage of URI developed pneumonia, and the infection resolved after receipt of oseltamivir plus ribavirin combination therapy. Twenty-two (88%) of the 25 patients were treated with an NA as monotherapy, with oseltamivir as the most common agent (administered to 21 patients [95%]). The remaining 3 patients were treated with combination therapy (oseltamivir plus ribavirin for 2 patients and oseltamivir plus rimantadine for 1 patient). The median duration of NA therapy was 6 days (range, 4-15 days) among all patients treated with antiviral therapy. The median duration of NA therapy was 5 days among patients with URI and 7 days among those with pneumonia. No major or moderate adverse effects were documented during NA therapy, and no patient received vaccination or chemoprophylaxis for influenza prior to infection. Three (38%) of the 8 patients who did not receive NA therapy died of influenza, compared with none of the 25 patients who received NA therapy ( ) ( figure 1) . The reasons for not P p .001 treating these 8 patients with NA therapy included late diagnosis coinciding with resolution of the infection in 4 patients, rapid deterioration leading to death due to influenza in 2 patients, treatment with amantadine therapy alone for 1 patient, and unknown cause for 1 patient. The majority of patients (29 patients [88%]), including the 3 who died, received broadspectrum antibiotic therapy for either suspected or documented coinfection. All 3 patients who died had influenza B pneumonia (3 of 11 patients with influenza B virus infection died vs. 0 of 22 patients with influenza A virus infection; ), with 1 P p .03 of the 3 patients presenting with a URI.
Discussion. To our knowledge, this is the largest reported series of patients with leukemia and influenza. Our finding that NA treatment was associated with a significantly lower influenza-specific mortality rate indicates that the use of NA therapy might improve outcome for these patients. We also found that lymphopenia at the time of presentation may identify patients with leukemia who are at high risk for the development of pneumonia.
Historically, in patients without cancer, secondary bacterial pneumonia (mainly with Streptococcus pneumoniae and Staphylococcus aureus) has been the most frequent serious complication of influenza and a major cause of influenza-associated mortality [14, 15] . In our population of patients with cancer, we found a significant number of mold infections (e.g., Aspergillus species and Fusarium species) that occurred after the onset influenza pneumonia, probably reflecting the net immunosuppression state of these patients.
The initial treatment options for uncomplicated influenza A virus infection include adamantane and NA therapies [7] . The results of noncontrolled studies have shown that oseltamivir therapy might be more effective than rimantadine therapy for the treatment of influenza in recipients of hematopoietic stem cell transplants [16] . Progression from an influenza URI to pneumonia has been reported in hematopoietic stem cell transplant recipients who were given amantadine or rimantadine therapy but not in those who were given oseltamivir or zanamivir therapy [16] . Ribavirin is a broad-spectrum antiviral agent with activity against influenza A and B viruses [17] [18] [19] . However, therapy with aerosolized ribavirin is a less desirable therapeutic alternative, given the high cost and the discomfort of ribavirin administration.
In our series, the use of NA therapy improved the outcome and should be considered for patients with leukemia who are infected with influenza virus. Our finding that no patient experienced moderate or severe adverse effects during NA therapy agrees with previous reports of immunocompetent patients that showed that NAs have a low toxicity profile [7] .
Because of the observational and retrospective nature of this study, our results should be considered preliminary, because the role of NA therapy in patients with leukemia who are infected with influenza virus has not been validated in randomized trials. However, clinicians should be aware that the use of NA therapy seems to improve the outcome of patients with leukemia and influenza.
